ROSEN, LEADING TRIAL ATTORNEYS, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. for the period between March 26, 2025, and November 4, 2025, due to alleged misleading statements regarding the safety and commercial viability of its product DCCR [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Soleno made false or misleading statements about the safety of DCCR, particularly concerning issues of excess fluid retention in clinical trial participants [5]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to potential adverse events post-launch [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6].